Know Cancer

forgot password

Phase II Trial of Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Phase 2
18 Years
Open (Enrolling)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Thank you

Trial Information

Phase II Trial of Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

- Since the purpose of the study is to determine the response rate of the 3 drug regimen,
everyone who participates will receive the same dose of the study drug, dasatinib and
the 2 standard drugs, fludarabine and rituximab.

- Participants will receive the drugs dasatinib, fludarabine, and rituximab at the
following time points through each cycle of treatment. A cycle of study treatment is
28 days. Dasatinib pills will be taken orally each day for the first 2 weeks of each
cycle. Fludarabine will be give intravenously on three days of each cycle (Days 3-5 in
the first cycle, days 1-3 after that). Rituximab will be given intravenously with a
total dose of 375 mg/m2 each cycle (split on Days 3+4 in the first cycle and at the
discretion of the treating physician after that on Days 1-3).

- The following procedures will be repeated throughout the study: medical history
review; physical exam; performance status test; blood tests and EKG. They will occur
daily during the first week of treatment, then weekly for the rest of cycle 1. After
cycle 1 these procedures will be done once a week for 4 weeks then once a month for 6

- Tumor assessments will be repeated once every 2 months for the first six months of the
study, and then once every 6 months after that.

- Blood samples will be obtained in the first 5 days of treatment for pharmacokinetic
studies and pharmacodynamic studies.

- Participants that are benefiting from the study treatment after the first cycle can
continue to receive an additional 6 cycles of study treatment.

Inclusion Criteria:

- CLL/SLL with cells positive by flow cytometry (or immunostaining) for CD19, CD23, and
CD5. Patients may be CD23 negative as long as they are also cyclin D1 negative or
t(11;14) negative.

- Participants must have received at least 1 prior regimen containing a purine analogue
or have received at least 2 chemotherapy regimens not containing a purine analogue.
Patients may be refractory to single-agent purine analogue treatment, but patients
may not be refractory to a combination of purine analogue with rituximab. Patients
may have received rituximab.

- 18 years of age or older

- Able to take oral medications

- ECOG Performance Status of 2 or better

- Adequate organ function to tolerate chemotherapy

- Women of childbearing potential must have a negative serum or urine pregnancy test
within 72 hours prior to the start of study drug administration and agree to use and
utilize an adequate method of contraception throughout treatment and for at least 4
weeks after study is stopped.

- Require treatment based on 1996 NCI-WG criteria updated in 2008 by the IWCLL

- Patient agrees to discontinue St. John's Wort while receiving dasatinib therapy and
stop at least 5 days before starting dasatinib.

- Patient agrees that IV bisphosphonates will be withheld for the first 8 weeks of

Exclusion Criteria:

- Pregnant or breastfeeding women

- Uncontrolled angina, congestive heart failure, or MI within 6 months

- Diagnosed or suspected congenital long QT syndrome

- Any history of clinically significant ventricular arrhythmias

- Prolonged QTc interval on pre-entry ECG

- Uncontrolled hypertension

- Hypokalemia or hypomagnesemia that is not corrected prior to dasatinib administration

- Patients should not be taking drugs that are generally accepted to have a risk of
causing Torsades de Pointes

- Known HIV positive

- Known significant bleeding disorder unrelated to CLL

- Any significant pleural or pericardial effusion

- Patients may not have another malignancy that is uncontrolled or requires treatment
within a year of starting this study.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response rate

Outcome Description:

To describe the response rate of complete respone and partial response to treatment with this drug combination.

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Philip Amrein, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Massachusetts General Hospital


United States: Institutional Review Board

Study ID:




Start Date:

July 2010

Completion Date:

Related Keywords:

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • CLL
  • fludarabine
  • rituximab
  • dasatinib
  • refractory
  • relapsed
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Lymphoma



Beth Israel Deaconess Medical Center Boston, Massachusetts  02215
Dana-Farber Cancer Institute Boston, Massachusetts  02115
Massachusetts General Hospital Boston, Massachusetts  02114-2617